SCOTUS agrees to hear Amgen revival bid

The dispute centres on a section of the Patent Act concerning 'enablement' | The US government had urged the court to deny the petition.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

SCOTUS rejects BMS vs Gilead patent clash

10 November 2022 Dispute over patent relating to a CAR-T cell therapy shunned by top court | Backing from Amgen, GSK and St. Jude's Children's Research Hospital over “exceedingly narrow” patent protection fails to convince Justices.

Americas

Fed Circ invaded jury’s role in Repatha case, says Amgen

25 November 2021 Amgen has urged the US Supreme Court to wade into its legal wrangle with Sanofi and Regeneron Pharmaceuticals over patents covering a cholesterol drug, Repatha.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

SCOTUS agrees to hear Amgen revival bid

More on this story

Editor's picks

Editor's picks

More features